CD269 (BCMA) Antibody, anti-human, REAfinity™
Synonyms: TNFRSF17, Bcm, BCMA
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
23 Citations5 Images
Clone:
REA315 | Vicky-1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD269 (BCMA) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 770
Vio Bright B515
Vio Bright V423
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-119-152, 130-118-975
Description:
Human myeloma cell line U266 cells were stained with CD269 (BCMA) antibodies or with the corresponding REA Control (S) antibodies (left peak) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application image
Extended validation for CD269 (BCMA) Antibody, anti-human, REAfinity™
Specificity
Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD269 (BCMA) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD269 (BCMA)-PE (REA315, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image
Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD269 (BCMA). A mixture of Human peripheral blood mononuclear cells (PBMCs) and U266 cells were stained with CD269 (BCMA) antibodies and with a suitable counterstaining. As a control, CD269 (BCMA) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD269 (BCMA) (REA315). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD269 (BCMA) Antibody, anti-human, REAfinity™
Overview

Clone REA315 recognizes the human CD269 antigen, a single-pass type III membrane protein which is also known as B cell maturation antigen (BCMA). CD269 is a member of the TNF-receptor superfamily that is preferentially expressed in mature B lymphocytes. It is the receptor for CD256 (TNFSF13, APRIL) and CD257 (TNFSF13B, BLyS, BAFF). CD269 promotes B cell survival and plays a role in the regulation of humoral immunity. Binding of CD269 to CD257 blocks the binding of CD257 to its receptor on the plasma membrane and inhibits CD257-triggered B lymphocyte costimulation. Overexpression of CD269 activates NF-κB and JNK, and this activation is potentiated by CD257.

Additional information: Clone REA315 displays negligible binding to Fc receptors.

Alternative names

TNFRSF17, Bcm, BCMA

Detailed product information

Technical specifications

Clone
REA315
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD269 (BCMA)
Molecular mass of antigen [kDa]
20
Distribution of antigen
B cells
Entrez Gene ID
RRID
AB_2801726, AB_2922369, AB_2751592, AB_2857746, AB_2801727, AB_2922372, AB_2921814, AB_2857740, AB_2751638

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD269 (BCMA) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support